• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

下尿路中的α1L-肾上腺素能受体亚型:人尿道与前列腺的比较

The alpha1L-adrenoceptor subtype in the lower urinary tract: a comparison of human urethra and prostate.

作者信息

Fukasawa R, Taniguchi N, Moriyama N, Ukai Y, Yamazaki S, Ueki T, Kameyama S, Kimura K, Kawabe K

机构信息

Department of Urology, Faculty of Medicine, The University of Tokyo, Japan.

出版信息

Br J Urol. 1998 Nov;82(5):733-7. doi: 10.1046/j.1464-410x.1998.00845.x.

DOI:10.1046/j.1464-410x.1998.00845.x
PMID:9839591
Abstract

OBJECTIVE

To identify the alpha1-adrenoceptor subtypes present in the human urethra, by comparing the affinity of prazosin for alpha1-adrenoceptors in the rabbit, dog and human prostatic urethra, and in the dog and human prostate.

MATERIALS AND METHODS

The study comprised samples of human prostate and prostatic urethra, obtained by open prostatectomy of patients with benign prostatic hyperplasia, and of the proximal urethra and prostate from male Beagle dogs and rabbits. Specimens were homogenized, filtered and pelleted by centrifugation. Nonspecific binding was determined in the presence of 1 mmol/L prazosin when assessing [3H]YM-617 (tamsulosin) binding, and 10 mmol/L phentolamine when assessing [3H]prazosin binding. Specific binding was defined as the difference between total binding and nonspecific binding.

RESULTS

The dissociation constant for [3H]prazosin in the human prostate (0.088 nmol/L) was less than that in the rabbit urethra (0.299 nmol/L), dog urethra (0.604 nmol/L), dog prostate (0.482 nmol/L) and human urethra (0.254 nmol/L). The affinity of prazosin was also investigated by determining the potency of the inhibition of [3H]YM-617 binding. The affinity of prazosin for alpha1-adrenoceptors in the human urethra (Ki, 2.5 nmol/L) was lower than its affinity for alpha1-adrenoceptors in the human prostate (Ki, 0.25 nmol/L) and all of the cloned subtypes (Ki, 0.26-0.44 nmol/L).

CONCLUSION

The alpha1L-adrenoceptor subtype is more prominent in the human, rabbit and dog urethra and dog prostate than in the human prostate.

摘要

目的

通过比较哌唑嗪对兔、犬和人前列腺尿道以及犬和人前列腺中α1 - 肾上腺素能受体的亲和力,确定人尿道中存在的α1 - 肾上腺素能受体亚型。

材料与方法

本研究包括通过对良性前列腺增生患者进行开放性前列腺切除术获得的人前列腺和前列腺尿道样本,以及雄性比格犬和兔的近端尿道和前列腺样本。将标本匀浆、过滤并通过离心沉淀。在评估[3H]YM - 617(坦索罗辛)结合时,在1 mmol/L哌唑嗪存在的情况下测定非特异性结合;在评估[3H]哌唑嗪结合时,在10 mmol/L酚妥拉明存在的情况下测定非特异性结合。特异性结合定义为总结合与非特异性结合之间的差值。

结果

[3H]哌唑嗪在人前列腺中的解离常数(0.088 nmol/L)低于兔尿道(0.299 nmol/L)、犬尿道(0.604 nmol/L)、犬前列腺(0.482 nmol/L)和人尿道(0.254 nmol/L)中的解离常数。还通过测定对[3H]YM - 617结合的抑制效力来研究哌唑嗪的亲和力。哌唑嗪对人尿道中α1 - 肾上腺素能受体的亲和力(Ki,2.5 nmol/L)低于其对人前列腺中α1 - 肾上腺素能受体的亲和力(Ki,0.25 nmol/L)以及所有克隆亚型的亲和力(Ki,0.26 - 0.44 nmol/L)。

结论

α1L - 肾上腺素能受体亚型在人、兔和犬的尿道以及犬前列腺中比在人前列腺中更突出。

相似文献

1
The alpha1L-adrenoceptor subtype in the lower urinary tract: a comparison of human urethra and prostate.下尿路中的α1L-肾上腺素能受体亚型:人尿道与前列腺的比较
Br J Urol. 1998 Nov;82(5):733-7. doi: 10.1046/j.1464-410x.1998.00845.x.
2
Characterization of alpha 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man.大鼠、兔、犬及人前列腺和前列腺尿道中α1-肾上腺素能受体亚型的特征分析
Eur J Pharmacol. 1993 Nov 16;249(3):307-15. doi: 10.1016/0014-2999(93)90527-o.
3
Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies.α1肾上腺素能受体拮抗剂在前列腺α1肾上腺素能受体上的药理选择性概况评估:结合、功能及体内研究
Br J Pharmacol. 1996 Jun;118(4):871-8. doi: 10.1111/j.1476-5381.1996.tb15480.x.
4
Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate.治疗良性前列腺增生的药物:在克隆的α1-肾上腺素能受体亚型及人前列腺中的亲和力比较
J Auton Pharmacol. 1996 Feb;16(1):21-8. doi: 10.1111/j.1474-8673.1996.tb00352.x.
5
In vitro studies on L-771,688 (SNAP 6383), a new potent and selective alpha1A-adrenoceptor antagonist.新型强效选择性α1A肾上腺素能受体拮抗剂L-771,688(SNAP 6383)的体外研究
Eur J Pharmacol. 2000 Dec 15;409(3):301-12. doi: 10.1016/s0014-2999(00)00854-2.
6
Identification of alpha 1-adrenoceptor subtypes in the human prostatic urethra.人前列腺尿道中α1-肾上腺素能受体亚型的鉴定。
Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):412-6. doi: 10.1007/pl00004962.
7
Tamsulosin: assessment of affinity of 3H-prazosin bindings to two alpha1-adrenoceptor subtypes (alpha1H and alpha1L) in bovine prostate and rat heart and brain.坦索罗辛:3H-哌唑嗪与牛前列腺、大鼠心脏和大脑中两种α1-肾上腺素能受体亚型(α1H和α1L)结合亲和力的评估。
Gen Pharmacol. 1998 Oct;31(4):597-600. doi: 10.1016/s0306-3623(98)00048-2.
8
Tamsulosin: alpha1-adrenoceptor subtype-selectivity and comparison with terazosin.坦索罗辛:α1肾上腺素能受体亚型选择性及其与特拉唑嗪的比较。
Jpn J Pharmacol. 1998 Nov;78(3):331-5. doi: 10.1254/jjp.78.331.
9
In vivo receptor binding of novel alpha1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia.新型α1肾上腺素能受体拮抗剂用于治疗良性前列腺增生的体内受体结合情况。
Life Sci. 1998;62(17-18):1585-9. doi: 10.1016/s0024-3205(98)00111-8.
10
Binding and functional characterization of alpha1-adrenoceptor subtypes in the rat prostate.大鼠前列腺中α1-肾上腺素能受体亚型的结合及功能特性研究
Eur J Pharmacol. 1999 Jan 29;366(1):119-26. doi: 10.1016/s0014-2999(98)00895-4.

引用本文的文献

1
Subtypes of functional alpha1-adrenoceptor.功能性α1-肾上腺素受体亚型。
Cell Mol Life Sci. 2010 Feb;67(3):405-17. doi: 10.1007/s00018-009-0174-4. Epub 2009 Oct 28.
2
Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells.α1肾上腺素能受体激活前列腺癌上皮细胞中的钙离子通透性阳离子通道。
J Clin Invest. 2003 Jun;111(11):1691-701. doi: 10.1172/JCI16293.
3
Receptor-coupled, DAG-gated Ca2+-permeable cationic channels in LNCaP human prostate cancer epithelial cells.LNCaP人前列腺癌上皮细胞中的受体偶联、二酰甘油门控的钙离子通透阳离子通道。
J Physiol. 2003 May 1;548(Pt 3):823-36. doi: 10.1113/jphysiol.2002.036772.
4
Alpha-blockers: an effective treatment for prostatitis?α受体阻滞剂:治疗前列腺炎的有效方法?
Curr Urol Rep. 2000 Aug;1(2):148-54. doi: 10.1007/s11934-000-0050-0.